Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug-Receptor Bonds01:25

Drug-Receptor Bonds

2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
2.7K
Enzyme Inhibition01:30

Enzyme Inhibition

77.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.9K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
Enzymes02:34

Enzymes

80.8K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
80.8K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures.

Signal transduction and targeted therapy·2026
Same author

Oligonucleotides Post-Synthetic Modifications: An Overview of Clickable Nucleoside Phosphoramidites Suitable for Solid-Phase Synthesis.

Chembiochem : a European journal of chemical biology·2026
Same author

Targeted Protein Degradation of NUDT5 Dissociates Catalytic Inhibition from Protein Loss in 6-Thioguanine Response.

Nature communications·2026
Same author

Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding.

Journal of medicinal chemistry·2026
Same author

Design principles of a membrane-spanning ubiquitin ligase.

Molecular cell·2026
Same author

Structural insights into cobalamin loading and reactivation of human methionine synthase.

Nature communications·2026

相关实验视频

Updated: Jun 6, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.4K

具有极高选择性的KEAP1的共价抑制剂.

Imre Fejes1, Piroska Markacz1, Janos Tatai1

  • 1Servier Research Institute of Medicinal Chemistry, Zahony u. 7., H-1031 Budapest, Hungary.

Journal of medicinal chemistry
|November 21, 2024
PubMed
概括

研究人员开发了针对NRF2-KEAP1通路进行细胞保护的新型,高度选择性的共价抑制剂. 这些化合物在没有基因毒性的情况下表现出强烈的体外和体内活性,提供了更安全的治疗方法.

更多相关视频

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

468
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.5K

相关实验视频

Last Updated: Jun 6, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.4K
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

468
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.5K

科学领域:

  • 生物化学 生物化学
  • 药理学 药理学是指药理学的学科.
  • 药物发现 药物发现 药物发现

背景情况:

  • 该NRF2-KEAP1通路对于细胞防御氧化应激至关重要,使其成为一个重要的治疗点.
  • 目前的KEAP1 (凯尔赫类ECH相关蛋白1) 的共价抑制剂缺乏选择性,导致潜在的副作用.

研究的目的:

  • 识别和优化KEAP1的新型共价抑制剂,提高选择性和降低毒性.
  • 研究开发的化合物的作用机制和选择性概况.

主要方法:

  • 现型选以确定最初的打击化合物.
  • 化学优化结构-活性关系研究.
  • 在体外和体内测试以评估细胞和生物活动.
  • 基因毒性测试. 基因毒性测试. 基因毒性测试.
  • 基于活动的蛋白质概况 (ABPP).
  • 进行X射线晶体学以确定结合模式.

主要成果:

  • 一种新的共价KEAP1抑制剂化学型被发现并优化.
  • 这种化合物表现出强大的细胞和体内疗效,可提高抗氧化剂反应元素 (ARE) 依赖基因的调节.
  • 在体外没有观察到基因毒性.
  • 化合物在ABPP中表现出广泛的选择性,以及与常见受体和激酶的极小的非目标相互作用.
  • X射线结晶学阐明了与KEAP1的特定相互作用以及选择性的基础.

结论:

  • 成功开发出了新型,高度选择性的共价KEAP1抑制剂.
  • 这些抑制剂为与压力相关的疾病提供了有前途的治疗策略,并改善了安全性.
  • 结构洞察力为进一步的药物设计提供了基础,以NRF2-KEAP1途径为目标.